Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Menu

    Nitrosamine

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,060Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA declines to approve Milestone's heart rhythm nasal spray
    FDA declines to approve Milestone's heart rhythm nasal spray

    29 Mar 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-milestone-pharmas-heart-rhythm-nasal-spray-2025-03-28/

    REUTERS
    29 Mar 2025
    Share Share
    Enforcement Report - Week of January 1, 2025
    Enforcement Report - Week of January 1, 2025

    01 Jan 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-1-2025-88420.pdf

    FDA
    01 Jan 2025
    Share Share
    Addressing Nitrosamine Risks in Pharmaceutical Manufacturing
    Addressing Nitrosamine Risks in Pharmaceutical Manufacturing

    10 Oct 2024

    // PRESS RELEASE

    https://www.api.polpharma.com/articles/addressing-nitrosamine-risks-in-pharmaceutical-manufacturing

    PRESS RELEASE
    10 Oct 2024
    Share Share
    Aptar's N-Sorb Accepted To FDA's Emerging Technology Program
    Aptar's N-Sorb Accepted To FDA's Emerging Technology Program

    23 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240923964121/en

    BUSINESSWIRE
    23 Sep 2024
    Share Share
    Nitrosating Agent Mitigation Strategy
    Nitrosating Agent Mitigation Strategy

    29 Aug 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_experts-opinion/2024-08-29/nitrosating-agent-mitigation-strategy/?widget=listSection

    CONTRACT PHARMA
    29 Aug 2024
    Share Share
    EMA seeks feedback on revised guideline on the chemistry of active substances
    EMA seeks feedback on revised guideline on the chemistry of active substances

    01 Aug 2024

    // RAPS

    https://www.raps.org/News-and-Articles/News-Articles/2024/8/Euro-Roundup-EMA-seeks-feedback-on-revised-guideli

    RAPS
    01 Aug 2024
    Share Share